Second Phase III trial for Teva/OncoGenex's custirsen in prostate cancer
This article was originally published in Scrip
Executive Summary
Teva and OncoGenex Pharmaceuticals have started the second Phase III trial evaluating their antisense drug custirsen (also known as OGX-011/TV-1011) as first-line therapy to treat castrate-resistant prostate cancer (CRPC).